Prelude Capital Management’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Prelude Capital Management’s Portfolio LUMO Stock Details LUMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-522	Closed	-$34K	–	2003
2018 Q1	$34K	Buy	+522	New	+$37K	﹤0.01%	1183
2017 Q4	–	Sell	-344	Closed	-$32K	–	1782
2017 Q3	$32K	Buy	+344	New	+$26.4K	﹤0.01%	1220
2017 Q2	–	Sell	-56	Closed	-$12K	–	1913
2017 Q1	$12K	Sell	56 -155	-73%	-$22.1K	﹤0.01%	1340
2016 Q4	$20K	Buy	+211	New	+$23.8K	﹤0.01%	1310
2016 Q3	–	Sell	-167	Closed	-$17K	–	1872
2016 Q2	$17K	Sell	167 -22	-12%	-$2.73K	﹤0.01%	1325
2016 Q1	$31K	Hold	189	–	–	﹤0.01%	1050
2015 Q4	$62K	Buy	189 +45	+31%	+$14.6K	0.01%	990
2015 Q3	$47K	Sell	144 -619	-81%	-$272K	0.01%	1081
2015 Q2	$304K	Buy	763 +285	+60%	+$121K	0.04%	451
2015 Q1	$235K	Buy	+478	New	+$185K	0.03%	591

Other funds holding LUMO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Prelude Capital Management's LUMO Position: Q2 2018 in Review

Prelude Capital Management sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q2 2018, closing a stake of 522 shares — an estimated $34K sold.

Prelude Capital Management first reported a position in LUMO in Q1 2015 and held it in 10 quarters. The position peaked at $304K in Q2 2015. 106 funds tracked by Wall St. Rank hold LUMO as of Q2 2018.

Prelude Capital Management reported no remaining Lumos Pharma, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
Prelude Capital Management sold 522 Lumos Pharma, Inc. Common Stock shares in Q2 2018, an estimated $34K.
Prelude Capital Management first reported a position in Lumos Pharma, Inc. Common Stock in Q1 2015 and held it in 10 quarters.
Prelude Capital Management's Lumos Pharma, Inc. Common Stock position peaked at $304K in Q2 2015.
106 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q2 2018.

Based on Prelude Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.